Wet Milling Impact on Particle Size | Webinar
Webinar Sob Demanda

Wet Milling Impact on Particle Size

Webinar Sob Demanda

Utilizing a Novel Wet Milling Crystallization Technique to Control Particle Size at Scale

Wet Milling Impact on Particle Size
Wet Milling Impact on Particle Size

This presentation details the development, understanding, and scale-up of an aseptic crystallization, which utilizes a novel wet milling during anti-solvent addition approach, that consistently delivers desired physical properties that result in an acceptable uniformity of the final drug product formulation.

Dan Minkler - Merck, Inc.
38 Minutes

The drug substance described is formulated as a sterile powder blend in a vial in combination with other sterile powder drug substances, and needs to fit into the existing formulation process and equipment.  The use of an aseptic blending operation requires that the final crystallization of the drug substance be performed in an aseptic environment as well.  Due to the nature of the sterile processing environment, sampling of the powder blend during processing to verify blend uniformity is not possible, and sampling of the crystal slurry during processing to ensure suitable physical properties is not feasible, so process adjustments based on in-process testing cannot be done. 

Presentation Overview

  • Active Pharmaceutical Ingredient (API) and Process Background
  • Wet Milling Process Characterization
    • Initial Assessment
    • Nucleation
    • Milling after nucleation
    • What actual controls particle size?
    • Further Studies: Understanding Mill Nucleation Mechanism
      • What role is the mill playing exactly when it comes to nucleation and generating more particles?
      • Experiment idea: only send fluid through the mill, filter out particles using a particle size analyzer
    • Scale-up Results, Acknowledgement and Questions
Wet Milling Impact on Particle Size
Dan Minkler - Merck & Co.

Guest Presenter
Dan Minkler earned a BS in Chemical Engineering from North Carolina State University. Dan worked for a year at Engineered Biopharmaceuticals doing process development on a novel spray drying application. He then took a position at Biogen working primarily on perfusion cell culture applications. Currently, Dan is in the Chemical Engineering Research and Development group (CERD) at Merck, Inc. focusing on the development and validation of an aseptic crystallization.

Thank you for visiting www.mt.com. We have tried to optimize your experience while on the site, but we noticed that you are using an older version of a web browser. We would like to let you know that some features on the site may not be available or may not work as nicely as they would on a newer browser version. If you would like to take full advantage of the site, please update your web browser to help improve your experience while browsing www.mt.com.